Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$2.39 - $3.5 $273,518 - $400,550
-114,443 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$2.86 - $4.33 $3,383 - $5,122
1,183 Added 1.04%
114,443 $343,000
Q4 2020

Feb 03, 2021

BUY
$2.93 - $4.3 $331,851 - $487,018
113,260 New
113,260 $392,000

About Aptinyx Inc.


  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.